

Phase I trial: Parexel code: PXL 269850

Submission date 29/06/2023	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 29/06/2023	Overall study status Deferred	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 30/04/2025	Condition category Other	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

Plain English summary of protocol

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Contact information

Type(s)

Principal investigator

Contact name

Dr David Steel

Contact details

Parexel Early Phase Clinical Unit
Harrow
United Kingdom
HA1 3UJ
+44 (0)7548098654
david.steel@parexel.com

Additional identifiers

Clinical Trials Information System (CTIS)

2022-003322-50

Integrated Research Application System (IRAS)

1006840

Protocol serial number

IRAS 1006840, PXL 269850, NMD1343-01-0001

Study information

Scientific Title

Phase I trial: Parexel code: PXL 269850 [The full scientific title will be published within 30 months after the end of the trial]

Study objectives

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Ethics approval required

Ethics approval required

Ethics approval(s)

1. approved 09/02/2023, London - Harrow Research Ethics Committee (Level 3, Block B, Whitefriars, Lewins Mead, Bristol, BS1 2NT, United Kingdom; +44 (0)207 104 8154; harrow.rec@hra.nhs.uk), ref: 23/LO/0007

2. approved 21/02/2023, MHRA (10 South Colonnade, Canary Wharf, London, E14 4PU, United Kingdom; +44 (0)20 3080 6000; info@mhra.gov.uk), ref: CTA 57479/0001/001-0001

Study design

Phase I first-in-human study to assess safety, tolerability and pharmacokinetics in healthy volunteers

Primary study design

Interventional

Study type(s)

Safety

Health condition(s) or problem(s) studied

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Interventions

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Intervention Type

Drug

Phase

Phase I

Drug/device/biological/vaccine name(s)

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Primary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Key secondary outcome(s)

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Completion date

31/05/2024

Eligibility

Key inclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Participant type(s)

Healthy volunteer

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.

Date of first enrolment

21/03/2023

Date of final enrolment

30/04/2024

Locations

Countries of recruitment

United Kingdom

England

Study participating centre
Parexel Early Phase Clinical Unit
Northwick Park Hospital
Watford Road
Harrow
United Kingdom
HA1 3UJ

Sponsor information

Organisation
NMD Pharma

Funder(s)

Funder type
Industry

Funder Name
NMD Pharma

Results and Publications

Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study are not expected to be made available due to the study being conducted in healthy volunteers

IPD sharing plan summary

Not expected to be made available

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			20/09/2023	No	No